Literature DB >> 31324113

The changes in FIGO staging for carcinoma of the cervix uteri.

B Sehnal, J Sláma, E Kmoníčková, O Dubová, M Zikán.   

Abstract

INTRODUCTION: The carcinoma of the cervix uteri is the fourth most common cancer in women worldwide and more than 85% of these cases occur in developing countries. Altogether 822 new cases were found in the Czech Republic during 2016 which means the incidence 15,3 new diseases/100,000 women.
OBJECTIVE: To provide an overview of changes in FIGO (International Federation of Gynecology and Obstetrics) staging for carcinoma of the cervix uteri with an incorporation of possible imaging methods and/or pathological findings, and clinical assessment of tumor size and extent. SETTINGS: Gynecologic Oncology Center, Department of Gynecology and Obstetrics, Hospital Na Bulovce and 1st Medical School of Charles University, Prague; Gynecologic Oncology Center, Department of Gynecology and Obstetrics, General Faculty Hospital and 1st Medical School of Charles University, Prague; Institute of Radiation Oncology, Hospital Na Bulovce, Prague.
METHODS: For this review, we have used the results of studies, review articles, and guidelines of oncogynecologic organisations on the cervical cancer published in English. They were identified through a search of literature using PubMed, MEDLINE-Ovid, Scopus and Cochrane Library with the keywords. We summarize the new classification, main changes compared to the former one and their clinical impact.
CONCLUSION: Lateral extension measurement is removed in the stage IA, the only criterion is the measured deepest invasion.

Entities:  

Keywords:  ESGO; FIGO; carcinoma; cervix uteri; staging

Mesh:

Year:  2019        PMID: 31324113

Source DB:  PubMed          Journal:  Ceska Gynekol        ISSN: 1210-7832


  1 in total

1.  Elastic Net-Based Identification of a Multigene Combination Predicting the Survival of Patients with Cervical Cancer.

Authors:  Hua Wang; Shu-Wei Li; Wei Li; Hong-Bing Cai
Journal:  Med Sci Monit       Date:  2019-12-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.